Shanghai ZJ Bio-Tech Co., Ltd (SHA:688317)
China · Delayed Price · Currency is CNY 20.93
-0.11 (-0.52%)
Feb 13, 2026, 3:00 PM CST
Shanghai ZJ Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 128.37 | 175.52 | 270.87 | 2,263 | 1,993 | 2,033 |
Other Revenue | 3.13 | 3.13 | 3.46 | 63.59 | 25.37 | 18.64 |
| 131.5 | 178.65 | 274.33 | 2,326 | 2,019 | 2,052 | |
Revenue Growth (YoY) | -36.38% | -34.88% | -88.21% | 15.23% | -1.62% | 692.72% |
Cost of Revenue | 211.89 | 216.07 | 282.13 | 1,131 | 762.4 | 535.62 |
Gross Profit | -80.39 | -37.42 | -7.8 | 1,196 | 1,256 | 1,517 |
Selling, General & Admin | 128.36 | 151.16 | 184.72 | 341.77 | 262.01 | 320.37 |
Research & Development | 61.77 | 58.78 | 61 | 104.62 | 108.79 | 52.43 |
Other Operating Expenses | 6.92 | 3.63 | 6.2 | 9.07 | 10.46 | 5.66 |
Operating Expenses | 204.06 | 221.98 | 253.27 | 461.8 | 386.64 | 385.93 |
Operating Income | -284.45 | -259.4 | -261.08 | 733.81 | 869.79 | 1,131 |
Interest Expense | -2.2 | -0.34 | -0.35 | -0.46 | - | - |
Interest & Investment Income | 82.21 | 113.26 | 67.54 | 42.54 | 17.16 | 2.61 |
Currency Exchange Gain (Loss) | 14.38 | 14.38 | 17.82 | 65.8 | -13.86 | -28.6 |
Other Non Operating Income (Expenses) | -0.17 | -2.57 | -1.22 | 1.85 | -3.68 | -0.33 |
EBT Excluding Unusual Items | -190.23 | -134.67 | -177.29 | 843.55 | 869.4 | 1,104 |
Gain (Loss) on Sale of Assets | -5.96 | -5.94 | -1.36 | -0.06 | - | - |
Asset Writedown | 24.02 | -16.55 | - | - | -0.03 | -0.27 |
Other Unusual Items | 6.6 | 6.6 | 22.02 | 57.99 | 27 | 5.19 |
Pretax Income | -165.57 | -150.57 | -156.63 | 901.48 | 896.37 | 1,109 |
Income Tax Expense | -21.73 | -23.11 | -19.78 | 141.21 | 137.85 | 177.19 |
Earnings From Continuing Operations | -143.83 | -127.46 | -136.86 | 760.27 | 758.52 | 932.01 |
Net Income | -143.83 | -127.46 | -136.86 | 760.27 | 758.52 | 932.01 |
Net Income to Common | -143.83 | -127.46 | -136.86 | 760.27 | 758.52 | 932.01 |
Net Income Growth | - | - | - | 0.23% | -18.61% | 1708.96% |
Shares Outstanding (Basic) | 189 | 190 | 193 | 193 | 191 | 146 |
Shares Outstanding (Diluted) | 189 | 190 | 193 | 193 | 191 | 146 |
Shares Change (YoY) | 0.40% | -1.30% | -0.36% | 1.51% | 30.46% | -0.76% |
EPS (Basic) | -0.76 | -0.67 | -0.71 | 3.93 | 3.98 | 6.38 |
EPS (Diluted) | -0.76 | -0.67 | -0.71 | 3.93 | 3.98 | 6.38 |
EPS Growth | - | - | - | -1.26% | -37.62% | 1722.86% |
Free Cash Flow | 67.55 | 58.1 | -163.03 | 510.41 | 143.88 | 1,067 |
Free Cash Flow Per Share | 0.36 | 0.30 | -0.85 | 2.64 | 0.76 | 7.31 |
Dividend Per Share | - | 0.110 | - | 1.200 | 1.365 | 1.600 |
Dividend Growth | - | - | - | -12.09% | -14.69% | 77.78% |
Gross Margin | -61.13% | -20.95% | -2.84% | 51.40% | 62.23% | 73.90% |
Operating Margin | -216.31% | -145.20% | -95.17% | 31.55% | 43.08% | 55.09% |
Profit Margin | -109.37% | -71.35% | -49.89% | 32.68% | 37.57% | 45.42% |
Free Cash Flow Margin | 51.37% | 32.52% | -59.43% | 21.94% | 7.13% | 52.01% |
EBITDA | -217.09 | -193.72 | -197.63 | 790.85 | 894.63 | 1,150 |
EBITDA Margin | -165.08% | -108.43% | -72.04% | 34.00% | 44.31% | 56.05% |
D&A For EBITDA | 67.37 | 65.69 | 63.45 | 57.03 | 24.84 | 19.68 |
EBIT | -284.45 | -259.4 | -261.08 | 733.81 | 869.79 | 1,131 |
EBIT Margin | -216.31% | -145.20% | -95.17% | 31.55% | 43.08% | 55.09% |
Effective Tax Rate | - | - | - | 15.66% | 15.38% | 15.97% |
Revenue as Reported | 131.5 | 178.65 | 274.33 | 2,326 | 2,019 | 2,052 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.